Header

         
 

Financial Highlights

     
   

2009

2008

 
 

EBITDA profit before exceptional items

£2.3m

£1.3m

 
 

Total revenue

£30.4m

£30.3m

 
 

Gross profit

£20.7m

£19.4m

 
 

Operational loss before exceptional items

£0.3m

£0.8m

 
         

Who we are
Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treatdermatological, oral care and gynaecological diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is already present in France, Italy and Spain and a complementary marketing partnernetwork that spans more than 90 countries.


What we do

  • We focus on the niche therapeutic areas of dermatology, oral health and gynaecolog
  • We extract full value from each of our brands by a combination of sales through our own country operations and international operations consisting of our extensive network of marketing partners to rapidly bring the products to market
  •  We utilise and combine acquired technologies and intellectual property to create new product concepts, adding to the product pipeline
 

 

Sinclair has delivered its second year of EBITDA profit. While the past year has not been without its challenges, we have responded to these by adapting our business to meet them head on.

 

Second year of EBITDA profit

The past 12 months have presented the global economy with some of the toughest challenges of recent times. The effects have been far reaching with no sector or geography left untouched. The life sciences, and especially pharmaceutical, industries have also felt the effects of the downturn with many wholesalers reducing the extent of their stocking to minimise their overall risk.

 

Against this backdrop Sinclair has delivered its second year of EBITDA profit. While the past year has not been withoutits challenges, we have responded to these by adaptingour business to meet them head on.

 

Read more